The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

BTOG 2021 | KRYSTAL-1 and CodeBreak 100: targeting KRAS G12C in lung cancer

Name: KRYSTAL-1 and CodeBreak 100: targeting KRAS G12C in lung cancer
Uploaded: 2021-04-23T00:00:00Z
Duration: 1 min 26 s
Description: Colin Lindsay, BSc, MBChB, MRCP, PhD, Christie NHS Foundation Trust, Manchester, UK, summarizes ongoing clinical trials of therapies which target KRAS G12C-mutant lung cancer, including the KRYSTAL-1 trial (NCT03785249) of adagrasib and the CodeBreak 100 trial (NCT03600883) of sotorasib. This interview took place during the 19th British Thoracic Oncology Group (BTOG) Annual Conference 2021.

Colin Lindsay • 23 Apr 2021

BTOG 2021

Lung Cancer Adagrasib Afatinib Antibodies Cetuximab Pembrolizumab Sotorasib

CodeBreaK 100 KRYSTAL-1

Colin Lindsay, BSc, MBChB, MRCP, PhD, Christie NHS Foundation Trust, Manchester, UK, summarizes ongoing clinical trials of therapies which target KRAS G12C-mutant lung cancer, including the KRYSTAL-1 trial (NCT03785249) of adagrasib and the CodeBreak 100 trial (NCT03600883) of sotorasib. This interview took place during the 19th British Thoracic Oncology Group (BTOG) Annual Conference 2021.

Disclosures

Colin Lindsay, BSc, MBChB, MRCP, PhD, has participated in an advisory role for Amgen and cbpartners; has participated in clinical trials with Amgen, Apollomics, BI, Mirati Therapeutics, Revolution Medicines and Roche; and has participated in a review paper coordinated by Amgen.